OncoMatch/Clinical Trials/NCT07104812
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Is NCT07104812 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Osilodrostat 1 MG for mild autonomous cortisol secretion.
Treatment: Osilodrostat 1 MG — The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: oral exogenous glucocorticoid therapy
Current use of oral exogenous glucocorticoid therapy
Cannot have received: opioid therapy
Exception: dose >20 MME/day
Current use of opioid therapy >20 MME/day
Cannot have received: injectable glucocorticoid
Use of injectable glucocorticoid within the last 6 weeks or anticipated glucocorticoid use during the study period.
Cannot have received: oral exogenous glucocorticoid therapy
Planned use of oral exogenous glucocorticoid therapy
Cannot have received: opioid therapy
Exception: dose >20 MME/day
Planned use of opioid therapy >20 MME/day
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify